| Adjuvant drug therapy for operable breast cancer. | |
| | |
MedLine Citation:
|
PMID: 8757274 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Breast cancer-the most common malignancy of lethal potential for women in the developed world-presents as two interrelated problems: (1) local disease in the breast and axillary lymph nodes, and (2) micrometastatic disease in distant sites. During the last century, advances in surgery and radiotherapy have led to high rates of control over local disease. In addition, heightened public awareness and the more widespread use of mammography have led to the more frequent detection of smaller cancers with better prognosis. Nevertheless, the problem of distant recurrence, leading almost inevitably to death, persists. Hence, there is considerable interest in integrating systemic therapy, which since mid-century has been shown to be active against advanced disease, into the treatment of primary breast cancer. The long-standing theoretical prediction of benefit from drug therapy as an adjunct to local control procedures has now been confirmed by several decades of clinical investigation. Long-term follow-up of seminal trials and the conduct of a crucial series of meta-analyses have established the ability of both hormonal therapies and chemotherapy to prolong disease-free and overall survival in nearly all groups of patients. Although the relative and absolute influences of drug therapies remain modest, if these were properly applied to the hundreds of thousands of patients diagnosed worldwide per year, the potential impact on public health would be significant. In addition, recent laboratory advances and clinical trial data have indicated several new directions that promise greater impact against occult disseminated disease. These include novel dosing and scheduling strategies, newer active agents, fresh biochemical targets, and different combinations of chemotherapy with hormonal therapy. |
| | |
Authors:
|
C A Hudis; L Norton |
Related Documents
:
|
21456944 - Tumor thickness predicts long-term complete response of facial basal cell carcinomas in... 23239254 - Fourth ventricle rosette-forming glioneuronal tumour in children: an unusual presentati... 11121624 - True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinic... 21658624 - Radioimmunotherapy in follicular lymphoma. 15963894 - Bloodstream infections and invasive mycoses in children undergoing acute leukaemia trea... 1617594 - Malignant thymoma. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Seminars in oncology Volume: 23 ISSN: 0093-7754 ISO Abbreviation: Semin. Oncol. Publication Date: 1996 Aug |
Date Detail:
|
Created Date: 1996-11-15 Completed Date: 1996-11-15 Revised Date: 2006-04-24 |
Medline Journal Info:
|
Nlm Unique ID: 0420432 Medline TA: Semin Oncol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 475-93 Citation Subset: IM |
Affiliation:
|
Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Age Distribution Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Breast Neoplasms / drug therapy*, surgery* Chemotherapy, Adjuvant / methods* Combined Modality Therapy / methods Cyclophosphamide / administration & dosage, therapeutic use Doxorubicin / administration & dosage Female Fluorouracil / administration & dosage, therapeutic use Hematopoietic Stem Cell Transplantation / methods Humans Methotrexate / administration & dosage, therapeutic use Neoplasm Recurrence, Local / pathology Radiotherapy, Adjuvant Risk Assessment Tamoxifen / administration & dosage |
| Chemical | |
Reg. No./Substance:
|
0/CMF regimen; 10540-29-1/Tamoxifen; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 51-21-8/Fluorouracil; 59-05-2/Methotrexate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Primary chemotherapy in operable breast cancer.
Next Document: Endocrine therapies of breast cancer.